- Home
- RDHL vs SNSE Comparison
RDHL vs SNSE Comparison
Compare RDHL & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- SNSE
- Stock Information
- Founded
- RDHL 2009
- SNSE 2005
- Country
- RDHL Israel
- SNSE United States
- Employees
- RDHL N/A
- SNSE N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- SNSE Health Care
- Exchange
- RDHL Nasdaq
- SNSE Nasdaq
- Market Cap
- RDHL 11.2M
- SNSE 12.3M
- IPO Year
- RDHL N/A
- SNSE 2021
- Fundamental
- Price
- RDHL $7.08
- SNSE $0.46
- Analyst Decision
- RDHL
- SNSE Strong Buy
- Analyst Count
- RDHL 0
- SNSE 3
- Target Price
- RDHL N/A
- SNSE $4.33
- AVG Volume (30 Days)
- RDHL 14.3K
- SNSE 894.4K
- Earning Date
- RDHL 11-19-2024
- SNSE 11-14-2024
- Dividend Yield
- RDHL N/A
- SNSE N/A
- EPS Growth
- RDHL N/A
- SNSE N/A
- EPS
- RDHL N/A
- SNSE N/A
- Revenue
- RDHL $3,707,000.00
- SNSE N/A
- Revenue This Year
- RDHL $224.90
- SNSE N/A
- Revenue Next Year
- RDHL $82.69
- SNSE N/A
- P/E Ratio
- RDHL N/A
- SNSE N/A
- Revenue Growth
- RDHL N/A
- SNSE N/A
- 52 Week Low
- RDHL $6.80
- SNSE $0.38
- 52 Week High
- RDHL $82.00
- SNSE $1.94
- Technical
- Relative Strength Index (RSI)
- RDHL 29.71
- SNSE 43.28
- Support Level
- RDHL $7.98
- SNSE $0.52
- Resistance Level
- RDHL $7.36
- SNSE $0.59
- Average True Range (ATR)
- RDHL 0.37
- SNSE 0.05
- MACD
- RDHL -0.12
- SNSE -0.01
- Stochastic Oscillator
- RDHL 0.00
- SNSE 8.72
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.